{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:02:08Z","timestamp":1791061328365,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Owing to the high prevalence of antibiotic resistance in\n                      <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      ) in China, bismuth-containing quadruple therapies have been recommended for\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      eradication. This study compared the efficacy and safety of quadruple regimens containing vonoprazan\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . esomeprazole for\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      eradication in a patient population in China.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This was a phase 3, multicenter, randomized, double-blind study. Patients with confirmed\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      infection were randomized 1:1 to receive quadruple therapy for 14\u00a0days: amoxicillin 1000\u00a0mg and clarithromycin 500\u00a0mg after meals, bismuth potassium citrate 600\u00a0mg before meals, plus either vonoprazan 20\u00a0mg or esomeprazole 20\u00a0mg before meals, all twice daily. The primary outcome was the eradication rate of\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      , evaluated using a\n                      <jats:sup>13<\/jats:sup>\n                      C urea breath test at 4\u00a0weeks after treatment. The non-inferiority margin was at 10%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study included 510 patients, 506 of whom completed the follow-up assessment. The primary analysis revealed eradication rates of 86.8% (210\/242) and 86.7% (208\/240) for vonoprazan and esomeprazole therapy, respectively (treatment difference: 0.1%; 95% confidence interval [CI]: \u22125.95, 6.17; non-inferiority\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.0009). Per-protocol analysis showed eradication rates of 87.4% for vonoprazan and 86.3% for esomeprazole (treatment difference: 1.2%; 95% CI: \u22125.03, 7.36; non-inferiority\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.0004). Vonoprazan and esomeprazole were well tolerated, with similar safety profiles.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Vonoprazan was found to be well-tolerated and non-inferior to esomeprazole for eradicating\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      in patients from China.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT04198363.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003437","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T21:00:07Z","timestamp":1739912407000},"page":"2938-2946","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3\u00a0study"],"prefix":"10.1097","volume":"138","author":[{"given":"Zhiqiang","family":"Song","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu\u00a0210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai East Hospital Affiliated Tongji University, Shanghai 200000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonghua","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Gu","sequence":"additional","affiliation":[{"name":"Takeda Development Center Asia, Shanghai 200000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited, Osaka 034-0041, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"R1-20260303","doi-asserted-by":"crossref","first-page":"e000472","DOI":"10.1136\/bmjgast-2020-000472","article-title":"Efficacy of second-line regimens for Helicobacter pylori eradication treatment: A systemic review and network meta-analysis","volume":"7","author":"Chang","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"key":"R2-20260303","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jgh.15751","article-title":"Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis","volume":"37","author":"Ren","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"R3-20260303","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000003348","article-title":"Impacts of Helicobacter pylori infection and eradication on gastrointestinal microbiota: An up-to-date critical review and future perspectives","author":"Li","year":"2024","journal-title":"Chin Med J"},{"key":"R4-20260303","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori\u00a0gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"R5-20260303","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin Med J"},{"key":"R6-20260303","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s10620-017-4536-8","article-title":"Primary antibiotic resistance of Helicobacter pylori in China","volume":"62","author":"Hu","year":"2017","journal-title":"Dig Dis Sci"},{"key":"R7-20260303","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"key":"R8-20260303","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomized, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"},{"key":"R9-20260303","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1751-2980.2010.00457.x","article-title":"Comparison of efficacy of triple versus quadruple therapy on eradication of Helicobacter pylori and antibiotic resistance","volume":"11","author":"Zheng","year":"2010","journal-title":"J Dig Dis"},{"key":"R10-20260303","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG Clinical Guideline: Treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R11-20260303","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"R12-20260303","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"R13-20260303","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.2147\/DDDT.S136240","article-title":"Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection","volume":"11","author":"Mascellino","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"R14-20260303","doi-asserted-by":"crossref","first-page":"e12889","DOI":"10.1111\/hel.12889","article-title":"Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study","volume":"27","author":"Song","year":"2022","journal-title":"Helicobacter"},{"key":"R15-20260303","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19\u00a0genotype","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-20260303","doi-asserted-by":"crossref","first-page":"9781212","DOI":"10.1155\/2019\/9781212","article-title":"Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials","volume":"2019","author":"Lyu","year":"2019","journal-title":"Biomed Res Int"},{"key":"R17-20260303","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1159\/000502287","article-title":"Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori","volume":"101","author":"Furuta","year":"2020","journal-title":"Digestion"},{"key":"R18-20260303","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2036.2012.05211.x","article-title":"Meta-analysis: Esomeprazole or rabeprazole vs. first generation pump inhibitors in the treatment of Helicobacter pylori infection","volume":"36","author":"McNicholl","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-20260303","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/jac\/dky183","article-title":"14\u00a0day sequential therapy versus 10\u00a0day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial","volume":"73","author":"Liou","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R22-20260303","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"R23-20260303","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1128\/AAC.02922-14","article-title":"Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection","volume":"58","author":"Hsu","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20260303","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"Helicobacter Pylori Study Group of Chinese Society of Gastroenterology. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin Med J"},{"key":"R25-20260303","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10238-018-0510-9","article-title":"Efficacies of different proton pump inhibitor-based 14-day bismuth\u2013furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: An open-label, randomized clinical trial","volume":"18","author":"Chen","year":"2018","journal-title":"Clin Exp Med"},{"key":"R26-20260303","doi-asserted-by":"crossref","first-page":"e12565","DOI":"10.1111\/hel.12565","article-title":"Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis","volume":"24","author":"Ko","year":"2019","journal-title":"Helicobacter"},{"key":"R27-20260303","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4166\/kjg.2019.73.1.26","article-title":"Effect of 7-day bismuth quadruple therapy versus 14-day moxifloxacin triple therapy for second-line Helicobacter pylori eradication therapy","volume":"73","author":"Kim","year":"2019","journal-title":"Korean J Gastroenterol"},{"key":"R28-20260303","doi-asserted-by":"crossref","first-page":"e12502","DOI":"10.1111\/hel.12502","article-title":"The \u201cthree-in-one\u201d formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice","volume":"23","author":"Zagari","year":"2018","journal-title":"Helicobacter"},{"key":"R29-20260303","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/jgh.15837","article-title":"Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients","volume":"37","author":"Hou","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"R30-20260303","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1751-2980.13166","article-title":"Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis","volume":"24","author":"Wang","year":"2023","journal-title":"J Dig Dis"},{"key":"R31-20260303","doi-asserted-by":"crossref","first-page":"e12940","DOI":"10.1111\/hel.12940","article-title":"Quadruple therapy with vonoprazan 20\u00a0mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial","volume":"28","author":"Lu","year":"2023","journal-title":"Helicobacter"},{"key":"R32-20260303","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study","volume":"65","author":"Murakami","year":"2016","journal-title":"Gut"},{"key":"R33-20260303","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/apt.14130","article-title":"Systematic review with meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication","volume":"46","author":"Jung","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R34-20260303","doi-asserted-by":"crossref","first-page":"e12495","DOI":"10.1111\/hel.12495","article-title":"Systematic review with metaanalysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori","volume":"23","author":"Li","year":"2018","journal-title":"Helicobacter"},{"key":"R35-20260303","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000454762","article-title":"A comparative study of a new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of Helicobacter pylori","volume":"94","author":"Tsujimae","year":"2017","journal-title":"Digestion"},{"key":"R36-20260303","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: Randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"R37-20260303","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bcp.14934","article-title":"Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication","volume":"88","author":"Huh","year":"2022","journal-title":"Br J Clin Pharmacol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T19:00:28Z","timestamp":1772564428000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":35,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003437","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"2024-09-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}